Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Numab AG
DescriptionAntibody blocking pain
Molecular Target Nav1.7 (SCN9A)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentDiscovery
Standard IndicationPain
Indication DetailsTreat chronic and severe pain
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today